organ growth mazor robot acquisit show posit trend
upgrad rate buy upgrad tp
previous deriv tp base forward price-to-earnings
multipl adjust ep provid
upsid potenti estim
top-lin revenu grow
estim base follow factor strong organ
revenu growth strong growth across group
region acquisit mazor robot newli launch
product strong growth oper perform adjust
plc deliv strong result
organ growth revenu declin
report basi due divestitur patient deep vein
thrombosi compress nutrit insuffici
busi
mdt oper profit increas
quarter adjust ep increas
gaap ep increas
emerg market revenu grew quarter
revenu china grew middl east africa grew
southeast asia grew eastern europ grew
south asia grew quarter
cardiac vascular group grew led growth
coronari structur heart csh strong high-teen growth
transcathet valv due sustain global demand
evolut valv csh also continu see strong adopt
resolut onyx drug-elut stent includ growth
compani name plc ordinari sharestickermdtstock ratingbuyupgradeindustri viewoverweightpositivepric oct week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth plc octob
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
minim invas therapi group grew led
growth surgic innov capit
convers surgic procedur open minim
invas driven new product
restor therapi group post best quarterli
perform histori grow led mid-teen
growth brain pain divis
diabet group best quarterli perform
decad growth due sustain strong
demand minim hybrid close loop system
plc mazor robot announc
compani enter definit merger
agreement acquir
outstand ordinari share mazor per
american depositori share il per
ordinari share cash total
net exist stake mazor cash
current price-to-earnings
due increas stock price price-to-earnings show
huge fluctuat last three year due volatil
stock price averag price-to-earnings
expect forward price-to-earnings multipl
expect organ revenu growth
expect adjust ep
recommend buy rate stock base
perform acquisit mazor robot
newli launch product
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date oct ex-dividend date sep last split factor new per last split date sep inform medtron plc octob
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg amort intang restructur oper interest incom special interest non-oper incom incom incom minor net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli plc octob
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item medtron plc octob
flow oper activ increas compar
increas due increas cash collect custom well decreas cash paid
supplier vendor certain litig payment cash paid incom tax
provid invest activ increas compar due
higher net sale invest partial off-set cash paid acquisit
use financ activ increas compar due
reduct commerci paper borrow
depreciation- defer incom oper increas decreas increas decreas current assets- decreas increas payables- decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end plc octob
plc deliv strong quarterli result growth revenu
organ due growth across segment region oper profit grew
adjust ep grew quarter
compar
net revenu decreas compar
revenu increas organ basi adjust
divestitur patient deep vein thrombosi compress
nutrit insuffici busi cardin occur
posit impact foreign currenc
total revenu repres total revenu
total revenu non-u develop market repres total
revenu total revenu emerg market repres
total revenu
develop market grew due strength europ
total revenu declin report basi
compar total revenu increas
constant currenc basi total revenu non-u develop
market increas compar
total revenu emerg market increas
compar
total revenu
increas
compar
cog decreas compar
cog revenu declin compar
non-gaap cog decreas due
divestitur lower-margin product conjunct divestitur
patient deep vein thrombosi nutrit insuffici busi
juli
gross margin basi compar
 expens increas compar
 revenu compar
remain commit acceler develop
meaning innov deliv better patient outcom appropri cost
lead enhanc qualiti life may valid clinic
sg expens increas slightli compar
sg revenu increas compar
non-gaap sg expens sg
expens includ acquisition-rel item well
cost incur direct result restructur program
amort intang asset compar
restructur charg increas
compar
oper expens compar
increas net expens due intang asset
charg associ exit busi three
oper profit increas compar
non-gaap oper profit non-gaap
oper margin
cog revenu
declin
compar
amort
intang asset
compar
non-oper incom compar
increas non-oper incom net due
increas invest gain recogn incom partial due
adopt new account guidanc
interest expens compar
decreas interest expens due decreas total debt oblig
averag
effect tax rate compar
decreas effect tax rate due impact certain tax
adjust oper tax adjust along year-over-year
chang oper result jurisdict non-gaap tax rate
compar
net incom increas compar
non-gaap net incom
gaap ep increas compar
non-gaap ep strong free cash flow
perform
interest expens
compar
decreas
interest expens due
decreas total
debt oblig
gaap ep increas
compar
oper four segment cardiac vascular group cvg
diabet group cvg segment contribut revenu mitg segment
contribut revenu rtg segment contribut revenu
diabet segment contribut revenu
revenu mitg
revenu rtg segment
contribut
revenu diabet
revenu
cardiac vascular group cvg cardiac vascular group segment
includ cardiac rhythm heart failur crhf coronari structur heart
csh aortic peripher vascular apv crhf contribut
segment revenu apv contribut segment revenu csh
contribut segment revenu
oper four segment cardiac vascular group cvg
diabet group cvg segment contribut revenu mitg segment
contribut revenu rtg segment contribut revenu
diabet segment contribut revenu
cardiac vascular group cardiac vascular group segment includ cardiac
rhythm heart failur coronari structur heart aortic peripher
vascular cvg consist annual growth line corpor perform
key growth driver are-
therapi innov driven transform innov meaning new
global emerg market growth drive doubl digit growth
cvg growth today drive futur growth
expand servic solut revenu stream led integr health
solut diagnosi referr manag servic patient manag
well shift toward valu base healthcar
enterpris excel program provid foundat leverag
optim drive increas profit cash flow gener
launch drive current growth
mdt tavr product market size contribut cvg
atrial fibril market size contribut cvg
endovenous/dcb market size contribut cvg
growth implant diagnost market size contribut
cvg growth
lvad market size contribut cvg growth
contribut cvg growth
cardiovascular segment driven continu innov goal
serv patient need said mike coyl execut vice presid
group presid cardiac vascular group cvg
cardiac vascular group cvg
cardiac vascular group segment revenu increas
compar cvg revenu perform
due strong low-doubl digit growth csh mid-singl digit growth
apv low-singl digit growth crhf constant currenc basi
cvg revenu increas compar
cvg revenu non-u develop market increas
compar cvg revenu
emerg market increas compar
develop manufactur market product diagnosi treatment
manag heart rhythm disord heart failur product includ
implant devic lead deliveri system product treatment
atrial fibril af product design reduc surgic site infect
inform system manag patient crhf devic
cardiac vascular
increas
compar
compar
crhf revenu increas compar
crhf revenu flat sale
growth due growth arrhythmia manag partial off-set
declin heart failur
growth arrhythmia manag due pace
due continu strong adopt micra transcathet pace
system azur wireless pacemak arrhythmia manag net sale
growth also benefit strong adopt tyrx absorb
antibacteri envelop expans value-bas health-car
heart failur strong growth mechan circulatori support sale
hvad system well continu demand crt-p quadripolar
pace system off-set declin crt-d devic
cardiac vascular group cvg
therapi treat coronari arteri diseas cad heart valv disord
product includ coronari stent relat deliveri system includ line
accessori well product repair replac heart
valv perfus system posit stabil system beat heart
revascular surgeri surgic ablat product
csh revenu increas compar
total revenu increas
compar
csh net sale growth due strong growth structur heart
coronari cardiac surgeri busi net sale growth structur
heart due global strength corevalv evolut
transcathet aortic valv system evolut continu global roll-
evolut transcathet aortic heart valv well continu
penetr intermedi risk
coronari net sale growth benefit growth drug-elut stent
includ resolut onyx guid cathet
aortic peripher vascular diseas manag apv apv divis consist
line product therapi treat aortic diseas aneurysm
dissect transect well peripher vascular diseas pvd
balloon stent angioplasti system carotid embol protect system
treatment vascular diseas outsid heart product line includ
rang endovascular stent graft accessori includ endur
abdomin aortic aneurysm aaa stent graft system valiant captivia
csh revenu increas
compar
growth benefit
growth drug-elut
stent includ
resolut onyx guid
cardiac vascular group cvg
apv revenu increas compar
total revenu increas
compar
sale growth due strong perform venas vein
closur system final approv reimburs payment
 center medicar medicaid servic
receiv januari
net sale growth also attribut growth percutan
translumin angioplasti pta balloon drug-coat balloon growth
intern market driven recent launch pact admir drug
coat balloon japan
group segment includ surgic innov si respiratori
gastrointestin renal divis si divis contribut
revenu divis contribut revenu
compar
compar
group segment includ surgic solut patient monitor recoveri
launch drive
focu group growth driver robust therapi innov
pipelin focus growth driver deliv strong revenu margin
well continu growth
drive establish emerg market strategi global growth
driver clear path leadership expect drive double-digit
growth sub-region within emerg market
focu value-bas healthcar drive value-bas healthcar
initi nok outcom pledg allow set price
fair reflect valu creat
leverag global size scale- focu global commerci
optim oper strategi drive long-term busi growth
sustain effici
mitg hold leadership posit mani attract market multipl growth
driver
advanc mi emerg market mitg compel
opportun increment market opportun shift patient
open surgeri mi
market size mi emerg market
robot assist surgeri market size long runway
specialti diversif strategi creat new avenu growth
lung health captur patient improv diagnost
optim treatment gynecolog health less invas
therapi optim treatment market size expect
growth low doubl digit
advanc paramet informat spectrum technolog
enabl earli warn deterior expertis monitor
clinic evid provid servic solut variou
product like capnographi bi monitor invo system vital
sync system market size growth rate expect
low double-digit
gastrointestin diseas mdt disrupt technolog
gastrointestin diseas led better outcom solut across
care continuum variou product like capsul endoscopi function
diagnost esophagu ablat liver tumor ablat market size
growth expect mid-single-digit
renal diseas mdt therapi address global need patient
provid payor comprehens end-to-end solut
market size growth expect mid-single-digit
mitg revenu
declin
compar
si divis revenu
total
revenu
mitg revenu declin compar
net sale affect divestitur
patient deep vein thrombosi nutrit insuffici
busi juli
mitg revenu declin compar
mitg revenu non-u develop market
declin compar
mitg revenu emerg market decreas
compar
surgic innov si si divis develop manufactur market
product therapi treat diseas condit address
surgeon surgic innov busi includ sale stapl vessel seal
fixat hernia mechan devic mesh hardwar surgic instrument
sutur electro surgeri product
si divis revenu total revenu
surgic innov net sale growth due new
product advanc advanc stapl includ ligasur
vessel seal instrument nano-co signia power
stapler tri-stapl endo stapl specialti reload
respiratori gastrointestin renal divis consist
respiratori monitor solut renal solut busi
respiratori monitor solut busi includ patient monitor
respiratori solut advanc ablat gi solut product line
renal solut busi includ renal access dialyz product
revenu total revenu
net sale declin result juli
divestitur patient deep vein thrombosi nutrit
insuffici busi net sale perform respiratori
gastrointestin renal benefit growth gi hepatolog
continu adopt microstream capnographi monitor product
growth airway ventil net sale
spine neuromodul surgic technolog neurovascular
consist sustain growth line corpor overal key growth
driver
surgic synergi procedur workflow link spinal implant
differenti enabl technolog goal improv outcom
procedur econom
build strong foundat neuromodul therapi new
cadenc innov disrupt technolog
improv live stroke patient market develop
rtg particip lead attract market segment rtg
drive futur growth
specialti therapi market size contribut rtg
growth wherea spine therapi neurosurgeri enabl technolog
market size contribut rtg growth
brain therapi market size contribut wherea
pain therapi market size contribut rtg
launch drive current growth
great confid rtg strategi innov pipelin
robust ever busi execut high level said
geoff martha medtron evp group presid
restor therapi group rtg rtg includ spine brain therapi
specialti therapi pain therapi divis spine divis contribut
revenu brain therapi contribut revenu specialti
therapi contribut revenu pain therapi contribut
revenu
rtg revenu increas compar
net sale growth driven brain therapi pain
rtg segment revenu increas
compar rtg revenu non-u develop
market increas compar
total revenu emerg market increas
compar
spine spine divis develop manufactur market line medic
devic implant use treatment spine musculoskelet
system product therapi treat rang condit affect
fractur spine stenosi spine divis also provid biolog
solut orthoped dental market concert surgic
technolog busi offer navig neuromonitor power
technolog design spine procedur
compar
rtg revenu
increas
compar
spine revenu increas compar
total revenu declin
compar
compar
net sale flat quarter surgic synergi strategi
result spine enabl technolog contribut strong
perform neurosurgeri busi
increas
compar
recent launch product includ elev solera voyag
fixat system prestig lp cervic disc contribut increment
net sale quarter
brain therapi brain therapi divis develop manufactur
market product therapi treat diseas vasculatur around
brain product includ coil neurovascular stent flow divers
product well access deliveri product support procedur
product offer includ pipelin pipelin flex embol devic
endovascular treatment larg giant wide-neck brain aneurysm
solitair fr revascular devic treatment acut ischem stroke
apollo onyx deliveri micro cathet
brain therapi revenu increas compar
total revenu increas
compar
brain therapi net sale growth due strong growth
neurovascular neurosurgeri neurovascular net sale growth due
adopt endovascular stoke treatment stent flow divers
neurosurgeri net sale growth due strong sale stealthstat
robot guidanc system visualas mri-guid laser ablat
specialti therapi specialti divis develop manufactur market
product therapi treat diseas condit ear nose
throat ent certain neurolog disord addit divis
develop manufactur market image-guid surgeri intra-op
imag system facilit surgic plan precis cranial spinal
sinu orthoped surgeri
specialti therapi divis revenu increas
compar total revenu
increas compar
net sale growth driven ent
neurostimul target drug deliveri system manag
chronic pain common movement disord spastic urolog
gastrointestin disord portfolio neurostimul system
includ recharg non-recharg devic select lead
use treat chronic back and/or limb pain
increas
compar
revenu increas
compar
portfolio product includ pain neurostimul system surescan
includ restoresensor recharg surescan mri
adaptivestim technolog devic use treat chronic
intract pain sever spastic associ cerebr palsi multipl
sclerosi spinal cord traumat brain injuri stroke
pain therapi divis revenu increas
compar total revenu increas
compar
increas net sale due intelli spinal cord stimul
platform evolv workflow algorithm snapshot report drug
deliveri pump also contribut growth
manag non-intens diabet therapi diabet servic
solut segment consist sustain growth corpor
averag key growth driver
close loop standard-of-care- increas cgm attach rate drive mdi
convers intern expans sale market
compound-annual-growth-rate
launch stand-alon cgm- smart cgm system focus
outcom sale market compound-annual-growth-rate
expans increas diagnost cgm glucos vital sign
manag sale market compound-annual-growth-rate
global leverag footprint cgm custom
launch drive current growth
diabet group diabet group divis develop manufactur
market integr diabet manag solut includ insulin pump
therapi continu glucos monitor cgm system therapi
manag softwar diabet group organ advanc
insulin manag aim emerg technolog divis
diabet group revenu increas
compar sale growth attribut
continu demand minim hybrid close loop system
offer latest smartguard technolog well higher sensor
attach util see integr pump user
growth intern market due strong sale
minim system europ asia pacif
diabet group revenu increas
compar diabet group revenu
non-u develop market increas
compar diabet group revenu
emerg market increas compar
aim quarterli revenu grew due on-going launch
minim hybrid close loop insulin pump system
growth continu strength minim system
emerg technolog quarterli revenu grew due
launch guardian connect cgm system sugar iq person
revenu increas
compar
due
launch guardian
sugar iq person
septemb plc mazor robot announc
compani enter definit merger agreement
acquir outstand ordinari share mazor
per american depositori share il per ordinari share
cash total net exist stake
mazor cash acquir
mazor found pioneer applic robot technolog
guidanc use spinal procedur market segment
leader mazor introduc system
launch next gener mazor system
date mazor system clinic use four contin
guid placement implant
procedur enabl minimally-invas spine surgeri becom
standard procedur mani hospit
mazor core technolog receiv food drug
administr clearanc subject
public lead spine robot market evid front mazor
holder fifti patent world-wide
acquisit expect close januari subject
satisfact customari close condit includ receipt regulatori
clearanc approv mazor sharehold transact
expect modestli dilut medtron adjust ep given
current strength busi compani expect absorb
dilut board director compani unanim
approv transact
transact build relationship origin may
multi-phas strateg equiti invest agreement medtron
mazor
plc
total
net
stake mazor cash
acquisit
expect close
satisfact
receipt regulatori
clearanc approv
mazor sharehold
expand partnership becom exclus world-wide
distributor mazor system lead success instal
mazor system sinc launch aim acceler
advanc adopt ra spine benefit patient
provid healthcar system broadli
acquisit mazor strengthen posit global
leader enabl technolog spine surgeri drive mazor robot
vision bring core technolog forefront global market
mazor proprietari core platform technolog includ mazor tm
robot guidanc system mazor surgical-guid
transform spinal surgeri freehand
procedur accur state-of-the-art guid procedur
combin market-lead spine implant navig
intra-op imag technolog mazor robotic-assist surgeri
ra system intend offer fully-integr procedur
solut surgic plan execut confirm
commit acceler adopt robotic-assist
surgeri transform spine care procedur solut
integr implant biolog enabl technolog
acquisit mazor add robotic-assist guidanc system mdt
expand portfolio enabl technolog intend
cultiv mazor legaci innov surgic robot site
team israel base futur growth
aim
acceler
advanc
adopt ra spine
benefit
patient provid
healthcar system
broadli
acquisit mazor
guidanc system
portfolio enabl
announc
launch
design simplifi
launch
coat balloon dcb
septemb plc announc launch
infin tm occipitocervical-upp thorac oct design
simplifi posterior cervic spine surgeri infin oct
complet procedur solut integr navig biolog
comprehens devic instrument creat
effici fusion procedur workflow upper back neck
plc announc fda approv investig
devic exempt initi single-arm studi evalu
corevalv evolut tm tavr system patient bicuspid aortic
valv low risk surgic mortal separ
receiv fda approv revis commerci label corevalv
evolut tavr system remov precaut treatment
bicuspid sever aortic stenosi patient deem intermedi
greater risk surgic aortic valv replac
plc announc start onyx one studi
 japan evalu one-month dual antiplatelet therapi
dapt high bleed risk patient implant resolut
onyx tm drug-elut stent de percutan coronari
august plc announc launch
pact tm admir tm drug-coat balloon dcb japan
news follow complet post-market clinic trial enrol
subject pact admir receiv approv last year
japanes ministri labor welfar mhlw treatment
peripher arteri diseas pad upper leg specif
thigh superfici femor arteri sfa behind knee poplit
arteri mhlw also grant reimburs approv
pact admir decemb
august announc offici launch
medtron inner circlesm patient engag program use
gamif applic game design element motiv
encourag peopl live diabet achiev better health outcom
plc commit creat sharehold valu execut
lead technolog industri leader technolog
continu innov invent disrupt
innovation- enhanc clinic outcom econom valu exist
invention- creat develop new therapi result new market
disruption- disrupt therapi exist market example-
redefin cardiac rhythm market product micra pace
drive shift faster grow geographi increas
follow differenti strategi channel optim
function capabl local
diversifi market enhanc technolog adopt sell
directli end custom
mdt organ revenu growth increas direct channel
indirect channel
tabl show region direct channel distribut
strategi use
acct acct
invoic pilot
econom valu lead develop new busi model
acceler technolog adopt econom valu
cvg segment adaptivcrt outcom protect coverag hf
hospit readmiss within month crt implant
rtg segment tyrx db pelvic health protect devic
implant relat infect within month devic implant
mitg segment respiratori compromis reduct code blue use
outcom valu base healthcar agreement
drive oper leverag drive oper margin expans
enterpris excel program focus expand margin enabl
reinvest enhanc long-term growth
global oper integr evolv global oper improv
qualiti deliveri cost cash flow
function optim evolv global function support long-term
growth sustain product
commerci optim oper commerci organ scale
improv custom servic experi
focus leverag breadth compani technolog
distribut cross sell share servic
improv convers strong focu improv free cash
flow convers target next year make free
cash flow prioriti realign manag incent focus everi
busi review primari focu upcom offic meet
determin reduc one-tim impact
plan drive sustain growth return execut strategi
expect organ revenu growth oper margin expans bp
adjust ep growth plan period convers ratio free cash
flow within next year return sharehold minimum
guidanc conclus
estim
organ
impli revenu
growth rate
sale growth estim organ impli
revenu growth rate
oper margin expect
adjust ep expect growth
adjust ep
expect
growth
tax rate expect
free cash flow expect
deliv growth revenu organ basi
due growth across busi segment region revenu
declin report basi due divestitur patient deep
vein thrombosi compress nutrit insuffici busi
also execut
enterpris excel
program result
margin expans
plan drive
throughout
organ
help balanc account
payabl receiv
improv
expenditur
also execut enterpris excel program result
margin expans quarter mdt oper profit increas
quarter adjust ep increas
ep increas program still
earli stage expect drive sustain cost save also
allow greater reinvest next sever year
cardiac vascular group grew led growth coronari
structur heart cvg segment invest micra av
allow access half pacemak market disrupt
minim invas therapi group grew led growth
surgic innov capit convers surgic procedur
open minim invas driven new product mitg segment
track robot assist surgeri platform
restor therapi group post best quarterli perform
histori grow led mid-teen growth brain pain divis
rtg segment invest next-gener cranial mount close
diabet group best quarterli perform decad
growth due sustain strong demand minim
hybrid close loop system diabet develop disrupt close
loop ecosystem advanc pump therapi cgm informat drive
dramat improv peopl manag condit easili
plan sustain revenu growth help
innov global plan organ revenu growth
estim organ growth develop market doubl digit
growth emerg market
target annual oper margin expans
help global oper function commerci optim
target cash convers next year plan drive
account throughout organ help balanc account
payabl receiv improv inventori optim disciplin
capit expenditur reduc one-tim expenditur
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
gross margin increas ttm basi compar due decreas cog
oper margin flat ttm basi net margin ttm basi
ep growth ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth plc octob
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale medtron plc octob
invest flow
sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale plc octob
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item medtron plc octob
balanc sheet item
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free plc octob
current price-to-earnings due increas stock price price-to-earnings
show huge fluctuat last three year due volatil stock price averag price-to-earnings
expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdershar report outvaluevanguard group inc wellington manag compani massachusett servic lazard asset manag price row associ artisan partner limit jp morgan top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard vanguard/windsor vanguard specialized-health spdr etf vanguard institut fund-institut mf seri trust i-mf valu vanguard specialized-dividend appreci dodg cox stock vanguard/wellington fund plc octob
develop launch infin tm oct spinal septemb plc announc launch infin tm occipitocervical-upp thorac oct design simplifi posterior cervic spine surgeri infin oct complet procedur solut integr navig biolog comprehens devic instrument creat effici fusion procedur workflow upper back neck acquir mazor roboticsseptemb plc global leader medic technolog mazor robot pioneer field robot guidanc system announc compani enter definit merger agreement acquir outstand ordinari share mazor per american depositori share il per ordinari share cash total net exist stake mazor cash acquir board director compani unanim approv transact announc commerci launch pact tm admir tm drug-coat balloon japanaugust plc announc full commerci launch pact tm admir tm drug-coat balloon dcb japan news follow complet post-market clinic trial enrol subject pact admir receiv approv last year japanes ministri labor welfar mhlw treatment peripher arteri diseas pad upper leg specif thigh superfici femor arteri sfa behind knee poplit arteri mhlw also grant reimburs approv pact admir decemb launch patient engag program leverag gamif help motiv engag patient live diabetesaugust announc offici launch inner circlesm patient engag program use gamif applic game design element motiv encourag peopl live diabet achiev better health outcom creat program address unmet patient need learn percent minim user interest program could help improv lives-includ effect manag diabetes-bi learn optim therapi experi plc octob
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit plc octob
consensu view analyst trend stock
forecast
forward price-to-earnings
compar
mdt avgfive-year growth forecast usdgrowth high day day day estim comparisonmdtindustri avg avgprice/earn yield plc octob
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate medtron plc octob
price target summarycrispidea isi trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext plc octob
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
stock price volatil quarter show upward trend sinc august
stock surg octob given return quarter averag
volum share trade period
stock volatil till april later show upward trend surg
stock given return past one year rang stock
stock show huge fluctuat last three year gave return last
stock dip surg
deliv result organ growth revenu due strong growth across
segment region oper profit grew non-gaap ep grew
quarter recommend buy rate stock tp base perform
new product launch
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
